Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

<p>Relationship between plasma SDX-7320 Cmax or AUC and change in platelets</p>

Сохранить в:

Библиографические подробности
Главный автор:	Monica M. Mita (21585118) (author)
Другие авторы:	Alain C. Mita (21585121) (author), Bradley J. Carver (18491067) (author), James M. Shanahan (18491064) (author), Benjamin A. Mayes (18491052) (author), Pierre J. Dufour (18491061) (author), David Browning (21585124) (author), Alfred Anderson-Villaluz (21585127) (author), John S. Petersen (18491055) (author), David J. Turnquist (18491058) (author), Peter Cornelius (18491049) (author)
Опубликовано:	2025
Предметы:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Protein biomarkers Pharmacology Pharmacokinetics and pharmacodynamics Phase I Clinical Trials
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы